Sequel II Sequencing Machine

The National Institutes of Health (NIH) intends to purchase Sequel II sequencing machine by Pacific Biosciences. The Sequel II is a DNA sequencing machine that offers long reads of single molecules. The sequencing depth achieved on this platform is delivered in tandem with high accuracy results. This machine can be used to deliver accurate consensus sequences for full-length cDNA sequencing projects, whole genomes, epigenetic analysis, and enriched targeted regions. To meet the increased demands of the projects described above the Genomics and Computational Biology Core (GCGC) requires the capability of long read (> 10,000 base pairs) sequencing to complement the existing short read (< 500 base pairs) technology in our facility. Training in instrument operation and maintenance, as well as data analysis, is included in this acquisition.

In accordance with the terms of FAR 12.603:

(i) This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6, as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; quotes are being requested and a written solicitation will not be issued.
(ii) The solicitation number for this requirement is NIH-OLAO-OD3-RFO-19-5285903 and this is a request for quotation (RFQ).
(iii) The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2005-101, dated October 26.
(iv) This acquisition is not a small business set-aside. The North American Industry Classification System (NAICS) Code for this acquisition is 334516 -- Analytical Laboratory Instrument Manufacturing, with a size standard of 500 employees.
(v) The specifications is in the attachment titled "Sequel II System Specifications"
(vi) This is a fixed-price requirement. Offeror should be aware that the Government shall perform a "best value analysis" and the selection for award shall be made based on the lowest price technically acceptable (LPTA) quote.

The following clauses apply to this acquisition:

(vii) The provision at 52.212-1, Instructions to Offerors-Commercial, applies to this acquisition and a statement regarding any addenda to the provision.
(viii) The provision at 52.212-2, Evaluation-Commercial Items, is applicable.
(ix) Offerors shall include a completed copy of the provision at 52.212-3, Offeror Representations and Certifications-Commercial Items, with its offer, or submit a printout to their Online Reps and Certs.
(x) The clause at 52.212-4, Contract Terms and Conditions-Commercial Items, applies to this acquisition. The clause, as well as any addenda to the clause, are included in the attachment entitled "Additional Provisions - Sequel II System".
(xi) The clause at 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Items, applies to this acquisition. Applicable clauses can be found in the attachment entitled "Additional Provisions - Sequel II System".
(xii) Any additional contract requirement(s) or terms and conditions (such as contract financing arrangements or warranty requirements) determined by the contracting officer to be necessary for this acquisition and consistent with customary commercial practices can be found in the attachment entitled "Additional Provisions - Sequel II System". There is no Defense Priorities and Allocations System (DPAS) rating assigned to this acquisition.
(xiii) In order to be considered for an award, an offeror must have completed the online electronic Representations and Certifications located at https://www.sam.gov in accordance with FAR 4.1201(a). By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in SAM at https://www.sam.gov/ prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation [Note: Lack of registration in the System for Award Management will make an offeror ineligible for award.] All responsible sources may submit an offer that will be considered by the Agency.
(xiv) Place of Delivery
Address: National Institutes of Health/ NIDCD
35A Convent Drive, Room 1F-103
Bethesda, MD 20892

(xv) Offers must be submitted no later than 5:00 P.M. (EST) on Wednesday, May 08, 2019. E-mail submissions to john.alozie@nih.gov by required response time. Fax submissions are not authorized. Requests for further information or questions concerning this requirement must be submitted in writing to john.alozie@nih.gov No later than Monday April 15, 2019. Please include the solicitation number on all your communications.
(xvi) Point of Contact
John Alozie, Contract Specialist, Phone 301-496-8413 or john.alozie@nih.gov

.